


WE CLAIM:

1. A meglumine salt represented by the formula:




wherein:

R_1 and R_2 are independently hydrogen or alkyl or taken together to form a carbonyl; and

Y is $(CH_2)_{0-5}$; and when R_1 and R_2 taken together form a carbonyl, Y is $(CH_2)_{1-5}$.

2. A meglumine salt represented by the formula:




wherein:

Y is $(CH_2)_{1-5}$.

3. The salt of Claim 2, wherein Y is (CH_2) .
4. The salt of Claim 2 wherein Y is $(CH_2)_2$.
5. The salt of Claim 2 wherein Y is $(CH_2)_3$.
6. The salt of Claim 2 wherein Y is $(CH_2)_4$.
7. The salt of Claim 2 wherein Y is $(CH_2)_5$.


8. A meglumine salt represented by the formula:



wherein:

Y is $(\text{CH}_2)_{0-5}$.

9. The salt of Claim 8, wherein Y is $(\text{CH}_2)_0$.
10. The salt of Claim 8 wherein Y is $(\text{CH}_2)_1$.
11. The salt of Claim 8 wherein Y is $(\text{CH}_2)_2$.
12. The salt of Claim 8 wherein Y is $(\text{CH}_2)_3$.
13. The salt of Claim 8 wherein Y is $(\text{CH}_2)_4$.
14. The salt of Claim 8 wherein Y is $(\text{CH}_2)_5$.
15. A meglumine salt selected from the group consisting of:
butanedioic acid, mono [4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl]ester, meglumine salt; acetic acid, [4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methyl-ethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]-, meglumine salt; and butanoic acid, 4-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methyl-ethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]-, meglumine salt.
16. A pharmaceutical composition comprising a meglumine salt represented by the formula:




wherein:

R_1 and R_2 are independently hydrogen or alkyl or taken together to form a carbonyl; and

Y is $(CH_2)_{0-5}$; when R_1 and R_2 taken together form a carbonyl, Y is $(CH_2)_{1-5}$; together with a pharmaceutically acceptable carrier.

17. A pharmaceutical composition comprising a meglumine salt represented by the formula:




wherein:

Y is $(CH_2)_{1-5}$;

together with a pharmaceutically acceptable carrier.

18. The pharmaceutical composition of Claim 17, wherein Y is (CH_2) .
19. The pharmaceutical composition of Claim 17 wherein Y is $(CH_2)_2$.
20. The pharmaceutical composition of Claim 17 wherein Y is $(CH_2)_3$.
21. The pharmaceutical composition of Claim 17 wherein Y is $(CH_2)_4$.
22. The pharmaceutical composition of Claim 17 wherein Y is $(CH_2)_5$.
23. A pharmaceutical composition comprising a meglumine salt represented by the formula:




wherein:

Y is $(CH_2)_{0-5}$; when R_1 and R_2 taken together form a carbonyl, Y is $(CH_2)_{1-5}$;

together with a pharmaceutically acceptable carrier.

24. The pharmaceutical composition of Claim 23, wherein Y is $(\text{CH}_2)_0$.
25. The pharmaceutical composition of Claim 23 wherein Y is (CH_2) .
26. The pharmaceutical composition of Claim 23 wherein Y is $(\text{CH}_2)_1$.
27. The pharmaceutical composition of Claim 23 wherein Y is $(\text{CH}_2)_3$.
28. The pharmaceutical composition of Claim 23 wherein Y is $(\text{CH}_2)_4$.
29. The pharmaceutical composition of Claim 23 wherein Y is $(\text{CH}_2)_5$.
30. A pharmaceutical composition comprising a compound of the formula:




wherein:

R_1 and R_2 are independently hydrogen or alkyl or taken together to form a carbonyl; and

Y is $(\text{CH}_2)_{0-5}$; when R_1 and R_2 taken together form a carbonyl, Y is $(\text{CH}_2)_{1-5}$;
together with meglumine and a pharmaceutically acceptable carrier.

31. A pharmaceutical composition comprising a compound of the formula:




wherein:

Y is $(\text{CH}_2)_{1-5}$;

together with meglumine and a pharmaceutically acceptable carrier.

32. The pharmaceutical composition of Claim 31, wherein Y is (CH_2) .

33. The pharmaceutical composition of Claim 31 wherein Y is $(\text{CH}_2)_2$.
34. The pharmaceutical composition of Claim 31 wherein Y is $(\text{CH}_2)_3$.
35. The pharmaceutical composition of Claim 31 wherein Y is $(\text{CH}_2)_4$.
36. The pharmaceutical composition of Claim 31 wherein Y is $(\text{CH}_2)_5$.
37. A pharmaceutical composition comprising a compound of the formula:




wherein:

Y is $(\text{CH}_2)_{0-5}$; when R_1 and R_2 taken together form a carbonyl, Y is $(\text{CH}_2)_{1-5}$; together with meglumine and a pharmaceutically acceptable carrier.

38. The pharmaceutical composition of Claim 37, wherein Y is $(\text{CH}_2)_0$.
39. The pharmaceutical composition of Claim 37, wherein Y is $(\text{CH}_2)_1$.
40. The pharmaceutical composition of Claim 37 wherein Y is $(\text{CH}_2)_2$.
41. The pharmaceutical composition of Claim 37 wherein Y is $(\text{CH}_2)_3$.
42. The pharmaceutical composition of Claim 37 wherein Y is $(\text{CH}_2)_4$.
43. The pharmaceutical composition of Claim 37 wherein Y is $(\text{CH}_2)_5$.
44. A method for the treatment of an inflammatory disorder, comprising administering to a host in need thereof an effective treatment amount of the salt of Claim 1.
45. The method of Claim 44, wherein the inflammatory disorder is arthritis.
46. The method of Claim 44, wherein the inflammatory disorder is rheumatoid arthritis.
47. The method of Claim 44, wherein the inflammatory disorder is osteoarthritis.

48. The method of Claim 44, wherein the inflammatory disorder is asthma.
49. The method of Claim 44, wherein the inflammatory disorder is multiple sclerosis.
50. The method of Claim 44, wherein the inflammatory disorder is psoriasis.
51. A method for the treatment of a cardiovascular disorder, comprising administering to a host in need thereof an effective treatment amount of the salt of Claim 1.
52. The method of Claim 51, wherein the cardiovascular disorder is atherosclerosis.
53. The method of Claim 51, wherein the cardiovascular disorder is post-angioplasty restenosis.
54. The method of Claim 51, wherein the cardiovascular disorder is coronary artery disease.
55. The method of Claim 51, wherein the cardiovascular disorder is small artery disease.
56. The method of Claim 51, wherein the cardiovascular disorder is angina.
57. A method for treatment of a disorder mediated by VCAM-1, comprising administering to a host in need thereof an effective treatment amount of the salt of Claim 1.
58. A method of treating an immune response, comprising administering to a host in need thereof an effective treatment amount of the salt of Claim 1.
59. The method of Claim 58, wherein the immune response is solid organ transplant rejection.
60. An organic amine salt represented by the formula:




wherein:

R_1 and R_2 are independently hydrogen or alkyl or taken together to form a carbonyl; and

Y is $(CH_2)_{0-5}$; when R_1 and R_2 taken together form a carbonyl, Y is $(CH_2)_{1-5}$.


61. An organic amine salt represented by the formula:



wherein:

Y is $(CH_2)_{1-5}$.

62. An organic amine salt represented by the formula:




wherein:

Y is $(CH_2)_{0-5}$.

63. A method for the treatment of an inflammatory disorder, comprising administering to a host in need thereof an effective treatment amount of the salt of any one of Claims 60-62.
64. A method for the treatment of a cardiovascular disorder, comprising administering to a host in need thereof an effective treatment amount of the salt of any one of Claims 60-62.
65. A method for treatment of a disorder mediated by VCAM-1, comprising administering to a host in need thereof an effective treatment amount of the salt of any one of Claims 60-62.

66. A method of treating an immune response, comprising administering to a host in need thereof an effective treatment amount of the salt of any one of Claims 60-62.

67. A pharmaceutical composition represented by the formula:




wherein:

R_1 and R_2 are independently hydrogen or alkyl or taken together to form a carbonyl; and

Y is $(CH_2)_{0-5}$; when R_1 and R_2 taken together form a carbonyl, Y is $(CH_2)_{1-5}$; together with a pharmaceutically acceptable carrier.

68. A pharmaceutical composition represented by the formula:




wherein:

Y is $(CH_2)_{1-5}$;

together with a pharmaceutically acceptable carrier.


69. A pharmaceutical composition represented by the formula:



wherein:

Y is $(\text{CH}_2)_{0-5}$; when R_1 and R_2 taken together form a carbonyl, Y is $(\text{CH}_2)_{1-5}$ together with a pharmaceutically acceptable carrier.

70. A compound of the formula:




wherein:

R_1 and R_2 are independently hydrogen or alkyl or taken together to form a carbonyl; and

Y is $(\text{CH}_2)_{0-5}$; when R_1 and R_2 taken together form a carbonyl, Y is $(\text{CH}_2)_{1-5}$ together with an organic amine, optionally in a pharmaceutically acceptable carrier.

71. A compound of the formula:




wherein:

Y is $(\text{CH}_2)_{1-5}$;

together with an organic amine, optionally in a pharmaceutically acceptable carrier.

72. A compound of the formula:




wherein:

Y is $(\text{CH}_2)_{0-5}$;

together with an organic amine, optionally in a pharmaceutically acceptable carrier.

73. The compound of any one of claims 70-72, wherein the organic amine is a primary amine.
74. The compound of any one of claims 70-72, wherein the organic amine is a secondary amine.
75. The compound of any one of claims 70-72, wherein the organic amine is a tertiary amine.
76. The compound of any one of claims 70-72, wherein the organic amine is substituted with one or more hydroxy or hydroxyalkyl groups.
77. The compound of claim 76, wherein the hydroxy or hydroxyalkyl substituted organic amine is cyclic.
78. The compound of claim 76, wherein the hydroxy or hydroxyalkyl substituted organic amine is acyclic.
79. The compound of claim 76, wherein the hydroxy or hydroxyalkyl substituted organic amine is an amino sugar.
80. The compound of claim 79, wherein the amino sugar is derived from a substituted and unsubstituted monosaccharide, disaccharide, oligosaccharide, or polysaccharide.
81. The compound of claim 79, wherein the amino sugar is derived from a substituted and unsubstituted monosaccharide.

82. The compound of claim 79, wherein the amino sugar is derived from an aldose or ketose.
83. The compound of claim 79, wherein the amino sugar is derived from a pyranose and furanose.
84. The compound of claim 79, wherein the amino sugar is derived from the group consisting of threose, ribulose, ketose, gentiobiose, aldose, aldotetrose, aldopentose, aldohexose, ketohexose, ketotetrose, ketopentose, erythrose, threose, ribose, deoxyribose, arabinose, xylose, lyxose, allose, altrose, glucose, mannose, gulose, idose, galactose, talose, erythrulose, ribulose, xylulose, psicose, fructose, sorbose, tagatose, dextrose, maltose, lactose, sucrose, cellulose, aldose, amylose, palatinose, trehalose, turanose, cellobiose, amylopectin, glucosamine, mannosamine, fucose, phamnose, glucuronate, gluconate, glucono-lactone, muramic acid, abequose, rhamnose, gluconic acid, glucuronic acid, and galactosamine.
85. The compound of claim 79, wherein the amino sugar is derived from a (L or D)-ribose.
86. The compound of claim 79, wherein the amino sugar is derived from a substituted and unsubstituted alditol.
87. The compound of claim 86, wherein the substituted and unsubstituted alditol is derived from the reduction of a monosaccharide.
88. The compound of claim 87, wherein the monosaccharide is a pyranose or furanose.
89. The compound of claim 86, wherein the substituted and unsubstituted alditol is represented by the formula



wherein:

X and Z are independently hydrogen; unsubstituted C₁₋₄ alkyl or substituted by one or more substituents selected from hydroxy, C₁₋₄ alkyl, or halogen; or taken together to form a carbocyclic ring;

R is hydrogen, C₁₋₈alkyl, or -(CH₂)₁₋₄OH; and

n is 1, 2, 3, 4 or 5.

90. The compound of claim 89, wherein n is 4.
91. A method for the treatment of an inflammatory disorder, comprising administering to a host in need thereof an effective treatment amount of the compound of any one of Claims 67-90. ✓
92. A method for the treatment of a cardiovascular disorder, comprising administering to a host in need thereof an effective treatment amount of the compound of any one of Claims 67-90.
93. A method for treatment of a disorder mediated by VCAM-1, comprising administering to a host in need thereof an effective treatment amount of the compound of any one of Claims 67-90.
94. A method of treating an immune response, comprising administering to a host in need thereof an effective treatment amount of the compound of any one of Claims 67-90.